Impra vascular graft tracking variance request needs clarification, FDA says.
This article was originally published in The Gray Sheet
IMPRA'S ALTERNATE PROCEDURES FOR TRACKING VASCULAR GRAFTS need clarification before FDA can approve them, the agency says in a recent response to an Impra petition filed in March 1994. FDA informs the company that "the agency has been unable, thus far, to determine whether it should grant the tracking variance requested in the petition, due to the need for the firm to provide and clarify certain information."
You may also be interested in...
Butterfly Network chose SPAC route with Longview Acquisition Corp. to scale its business and expand into the home market in 2021.
Regulatory review resource-intensive cell and gene therapy licensing applications are rolling toward US FDA along expedited pathways, while complete response letters and missed goal dates start to stack up under pandemic inspection constraints.
With Warp Speed Decisions Already Made, Transitioning To Biden Admin Should Be No Trouble, Slaoui Says
As vaccines near availability, Moncef Slaoui says his full-time role at OWS may be ending. He has not met with the Biden Transition team, but notes that other Warp Speed officials have.